PF-Atlas › Clinical Trials › NCT04396756

Evaluation of Efficacy and Safety of PLN-74809 in Patients With Idiopathic Pulmonary Fibrosis

PLN-74809 · Phase 2

Registry ID
NCT04396756
Phase
Phase 2
Status
Completed
Drug / intervention
PLN-74809
Sponsor
Pliant Therapeutics, Inc.
Start
2020-03-03
Enrollment
120
Locations
20

About this trial

A Phase 2a, multicenter, 4-part, randomized, double-blind, dose-ranging, placebo-controlled study to evaluate the safety, tolerability, and PK of once-daily treatment with PLN-74809 in participants with idiopathic pulmonary fibrosis.

View NCT04396756 on ClinicalTrials.gov →

Explore related

PLN-74809 — Treatment profileAll PLN-74809 trialsAll IPF trials

Related trials

PLN-74809 — INTEGRIS-IPFPLN-74809 — NCT04072315PLN-74809 — NCT06097260
Medical disclaimer. This page summarizes public trial data for NCT04396756 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.